Phase 4 Hepatitis C Trial, Recruiting NCT06953479 Sponsor: Lifespan Condition: Hepatitis C
Back to Hepatitis C

Phase 4 Hepatitis C Trial, Recruiting

NCT06953479
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are currently incarcerated at RIDOC (Rhode Island Department of Corrections)
  • People who are 18 years of age or older
  • People who are awaiting trial and have not yet been sentenced
  • People who speak English
  • People who have an active Hepatitis C (HCV) infection, confirmed by a blood test within the past 90 days
  • People who have not previously been treated for their current Hepatitis C infection
  • People who do not have cirrhosis (scarring of the liver), based on a blood test result within the past 90 days
  • People who report using drugs by injection
  • People who are willing and able to be contacted after release from jail
  • People who intend to continue taking the medication after leaving jail
  • People who wish to take the medication Sofosbuvir/Velpatasvir (also called Epclusa)

Who may not be able to join:

  • People who have cirrhosis (significant liver scarring), based on a blood test or clinical signs within the past 90 days
  • People who test positive for Hepatitis B
  • People who are currently pregnant or breastfeeding
  • People who have a known allergy or sensitivity to any components of the study medication
  • People who have a serious illness that requires hospital admission at the time of enrolment
  • People who have a documented severe and persistent mental illness on record with RIDOC
  • People who have a history of serious liver complications, such as fluid build-up in the abdomen, certain types of infections, confusion caused by liver failure, kidney problems related to liver disease, or bleeding from veins in the oesophagus
  • People who are HIV-positive and have had a serious HIV-related infection within the past 90 days

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Lifespan
Registry
ClinicalTrials.gov
Start date
11 June 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

HCV Cure Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov